ALISO VIEJO, Calif. & SAN ANTONIO--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq:CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, announced today that new data will be presented during the San Antonio Breast Cancer Symposium, validating Clarient’s new prognostic breast cancer profile – Clarient InsightTM Dx.
